Sebastian Dümcke

Jan 10, 2022

Clemedi Update Q4 2021

Business Development

We have signed an evaluation agreement with Thyrocare, a large Indian network of diagnostic labs. They will evaluate our tuberculosis diagnostic in the coming year.

Clemedi conducted interviews with key-opinion leaders to validate the product-market fit of current and future products. Also, Niko attended three (virtual) conferences, South Summit, Wolf Summit and DxPx Europe. In total we got 19 interactions to follow-up with.

Company Development

We are happy to have Dr. Turlough Neary join our team in November as Data Scientist. He will support the development of our AI algorithms. Welcome Turlough!

Clemedi has been invited to pitch at the Roche Diagnostics internal startup day. It was a fun event, where we could get an insight on how such a large company operates.

Clemedi has also been featured in the UZH Magazin 3/21 on page 9 (german only).

Product Development

Software Development

Our new user interface is connected to our backend and ready to be tested by user. It is deployed here: http://tuberculini.clemedi.com

Lab Development

Pauline is trained on the use of our sequencer and all aspects of our test and will start generating important data in the first weeks of the new year.

Fundraising

The team has started fundraising of the next financing round, expected to close in the second half of this year.

To close this report, we would like to wish everybody a happy new year full of success. Clemedi is excited about 2022 as we expect a lot of good things to happen.

Clemedi Update Q3 2021

Business Development

We have been selected by Swissnex to join the India Market Entry camp. Our team will travel to India to strengthen its market entry strategy for this important market.

We are also negotiating OEM agreements with our suppliers, enabling us to sell a Clemedi branded box with all reagents. You can see our current renders for what this box might look like below.

Company Development

We have new team pitcures. During a fun photoshoot we generated picture material for the core team members.

We welcome Pauline as new addition to the team. She will be supporting development in the lab and serve as liaison to the University of Berne.

Product Development

Software Development

Implemented several new features in our software to help physicians interpret our results within known reference points. For this we added a WHO curated list of resistance confering mutations as well as generated known line-probe assay blots in the user interface as seen below.

Lab Development

We kicked off documentation of all product specifications and parameters under an ISO13485 quality management system with the help of Effectum Medical.

Fundraising

We are closing a last addition to our first financing round to further help us reach our goals. Details will follow.

Clemedi Update Q2 2021

Business Development

We finalised the license agreement with the University of Zurich. This license gives us the exclusive right to use on the patent application necessary to commercialize the Tuberculini product. We have made progress with potential collaboration partners in India, who are interested in our technology.

Company Development

In our last General Assembly we have created the possibility to conduct future General Assemblies in digital format in line with the move to digitize business processes to increase efficiency.

Product Development

Software Development

We have translated the user interface templates that were validated in a small-scale user study into an interactive and clickable online application that can be hosted in the cloud.

Below you can see mockups of the registration screen as well as the dashboard that shows a list of analyses and the menu for the functionality of the application.

Lab Development

Work packages financed by the Innosuisse Grant we obtained last year are on track. Experiments are ongoing at our partner site at the University of Bern. We also have contracted other international sites in Italy, Pakistan and Uganda to support in validating our Tuberculini product.

Fundraising

We were able to close a convertible round of CHF 385k from several Angel Investors end of June. The financing, will enable us to reach our the design freeze of Tuberculini, the first application on our Disease Management Platform as well as plan the upcoming clincial study.